Hepatitis Tests, Profiles, and Panels by Thyrocare

• Anti Hepatitis B Envelope Antigen (AHBe)
• Hepatitis B Envelope Antigen (HBeAg)
• Anti Hepatitis B Core Antigen – IgM
• Anti Hepatitis B Core Antigen – Total
• Anti Hepatitis B Surface Antigen – Total
• Hepatitis B Surface Antigen (HBsAg)
• Anti Hepatitis C Virus (Anti-HCV)
• Anti Hepatitis A Virus (IgM)
• Anti Hepatitis A Virus – Total
• Anti Hepatitis E Virus (IgM)

• Liver function markers including AST, ALT, bilirubin fractions, alkaline phosphatase
• Gamma glutamyl transferase
• Serum proteins and albumin
• Complete hemogram (CBC)
• HbA1c and average blood glucose

Used when broader hepatitis marker coverage across A, B, C, and E is required together with liver and blood-health parameters.

• Hepatitis B Surface Antigen (HBsAg)
• Hepatitis B Envelope Antigen (HBeAg)
• Anti Hepatitis B Envelope Antigen
• Anti Hepatitis B Core Antigen – IgM
• Anti Hepatitis B Core Antigen – Total
• Anti Hepatitis B Surface Antigen – Total

• Liver function markers including AST, ALT, bilirubin fractions
• Gamma glutamyl transferase
• Serum protein and albumin
• Complete hemogram
• HbA1c and average glucose

Focused Hepatitis B marker profile combined with supportive liver and blood parameters.

• Marker-wise result pages for hepatitis A, B, C, and E
• Clinical significance notes for individual markers
• Methodology references such as CMIA, ELISA, and photometry-based reporting shown on the lab pages
• Liver function marker page with reference intervals
• HbA1c and average blood glucose page
• Complete hemogram page with counts, indices, and platelet parameters
• Conditions of reporting and report structure notes

HBsAg is used as a screening marker for Hepatitis B infection. It appears around 2 to 3 weeks before onset of illness, reaching a peak during the illness phase, and disappearing in self-limited infection within about 3 to 6 months. Persistence beyond that pattern can be seen in carrier states.

Anti-HBs is a marker associated with recovery or immunity after Hepatitis B infection. The report notes state that this antibody usually appears after HBsAg has disappeared from the blood and that a level of 10 mIU/mL or more is regarded as protective against Hepatitis B viral infection.

HBeAg is described in the report as a marker of active viral replication in Hepatitis B. It is detected in the early phase after HBsAg and is associated with increased numbers of infectious virions and the presence of HBV DNA and DNA polymerase in serum.

Anti-HBe becomes clinically relevant after the disappearance of HBeAg. The report notes indicate that seroconversion from HBeAg to Anti-HBe during acute Hepatitis B is usually linked with resolution of infection and reduced infectivity.

Anti-HBc IgM supports the assessment of recent or acute Hepatitis B infection. It appears shortly after HBsAg and usually disappears within about six months, making it useful in the laboratory.

Anti-HBc Total indicates exposure to the Hepatitis B virus. It appears during the incubation phase with HBsAg, shows infection with HBV, and remains positive for life in most individuals.

Anti-HAV IgM supports the assessment of acute Hepatitis A infection. The report notes state that IgM Anti-HAV appears in the acute phase, is nearly always detectable at symptom onset, and in many cases persists through the first month of illness and can remain detectable for up to about six months. Anti-HAV Total has a different role; the report notes that after infection, Anti-HAV remains detectable for a lifetime and helps in evaluating past exposure or immunity.

Anti-HEV IgM is used in the evaluation of Hepatitis E. The report notes describe Hepatitis E as usually an acute infection and state that pregnant women are at higher risk of fulminant hepatic failure. Interpretation still depends on the overall clinical picture and timing of testing.

Anti-HCV is used in screening for Hepatitis C exposure. The report notes identify HCV as a major cause of transfusion-associated non-A, non-B hepatitis and state that repeated reactive anti-HCV screening results should be confirmed with supplementary or nucleic acid-based testing.

The panels include bilirubin fractions, alkaline phosphatase, GGT, AST, ALT, serum proteins, albumin, globulin, and the albumin-globulin ratio. These parameters help assess liver cell injury, cholestatic pattern, bilirubin handling, and protein synthesis status alongside viral markers.

The hepatitis panel also includes HbA1c with average blood glucose and a complete hemogram. HbA1c adds metabolic context, while CBC provides supporting information on white cells, red cells, hemoglobin, platelet count, and differential counts. These do not diagnose hepatitis by themselves, but they add broader pathology context to the panel.

1. Select the required panel.
2. Share patient details (name, age, gender, complete address with area PIN code, email id and phone number) through WhatsApp.
3. Select date and time for home collection appointment.
4. You will receive booking confirmation within a few minutes.
5. A trained phlebotomist will collect the sample as per the schedule.
6. Samples will be processed at Thyrocare’s NABL-accredited and ISO-certified labs.
7. You will receive digital reports as per the TAT.

The Complete Hepatitis Panel includes hepatitis markers across Hepatitis A, B, C, and E, along with supportive pathology parameters such as liver function markers, HbA1c, and complete hemogram. The Complete Hepatitis B Profile is focused on Hepatitis B markers with supportive pathology parameters.

Both panels require a blood sample.

Fasting is not required for these panels. Since the package also includes supportive pathology parameters such as liver function markers and HbA1c, avoiding a very heavy meal before collection can help maintain cleaner pre-analytical conditions.

The stated reporting time for the Complete Hepatitis Panel is 48 hours.

The stated reporting time for the Complete Hepatitis B Profile is 56 hours.

Yes. The broader hepatitis panel groups multiple viral markers with liver-related and blood-related parameters so the laboratory pattern can be reviewed in a wider pathology context. The Hepatitis B profile focuses on the Hepatitis B marker pattern specifically.

Reports are delivered digitally through the registered email address and WhatsApp number after laboratory processing is completed.

Home sample collection is available in many serviceable locations. Availability depends on city coverage and slot availability at the time of booking.

Yes. You can share the patient’s name, age, gender, address, PIN code, phone number, and email details at the time of booking.

Yes. Both panels include supportive pathology parameters such as liver function markers and complete hemogram. The broader hepatitis panel also includes markers across Hepatitis A, B, C, and E.